Reliability of COVID-19 data: An evaluation and reflection

April R. Miller^{1¶}, Samin Charepoo^{2¶}, Erik Yan^{3¶}, Ryan W. Frost⁴, Zachary J. Sturgeon⁵, Grace Gibbon⁶, Patrick Balius⁷, Cedonia S. Thomas⁸, Melanie A. Schmitt⁹, Daniel A. Sass¹⁰, James B. Walters¹¹, Tracy L. Flood¹¹, Thomas A. Schmitt^{11*}, on behalf of the COVID-19 Data Project[^]

¹ Department of Public Health, Simmons University, Boston, Massachusetts, United States of America

² Department of Data Science and Neuroscience, Simmons University, Boston, Massachusetts, United States of America

³ Duke Global Health Institute, Duke University, Durham, North Carolina, United States of America

⁴ Department of Mathematics & Statistics, Boston University, Boston, Massachusetts, United States of America

⁵ Department of Physical Sciences, University of California San Diego, La Jolla, California, United States of America

⁶ Global School of Public Health, New York University, New York City, New York, United States of America

⁷ Division of Environmental Health Sciences, University of Minnesota, Minneapolis, Minnesota, United States of America

⁸ Department of Biology, Tougaloo College, Tougaloo College, Tougaloo, Mississippi, United States of America

⁹ Pediatric Ophthalmology and Adult Strabismus, Department of Ophthalmology and Visual Sciences, University of Wisconsin-Madison, Madison, Wisconsin, United States of America

¹⁰ Department of Management Science and Statistics, The University of Texas at San Antonio, San Antonio, Texas, United States of America

¹¹ BroadStreet, Milwaukee, Wisconsin, United States of America

* Corresponding author
Email: tom@broadstreet.io (TS)

¶ Authors contributed equally to this work

[^] All authors were members of (or participated in) the COVID-19 Data Project

Abstract

Importance: The rapid proliferation of COVID-19 has left governments scrambling, and several data aggregators are now assisting in the reporting of county cases and deaths. The different variables affecting reporting (e.g., time delays in reporting) necessitates a well-documented reliability study examining the data methods and discussion of possible causes of differences between aggregators.

Objective: To statistically evaluate the reliability of COVID-19 across aggregators.

Design, Setting, and Participants: Cases and deaths were collected daily by volunteers via state and local health departments, as primary sources and newspaper reports, as secondary sources. In an effort to begin comparison for reliability statistical analysis, BroadStreet collected data from other COVID-19 aggregator sources, including USAFacts, Johns Hopkins University, New York Times, The COVID Tracking Project.

Main Outcomes and Measures: COVID-19 cases and death counts at the county and state levels.

Results: Lower levels of inter-rater agreement were observed across aggregators associated with the number of deaths, which manifested itself in state level Bayesian estimates of COVID-19 fatality rates.

Conclusions and Relevance: A national, publically available data set is needed for current and future disease outbreaks and improved reliability in reporting.

Introduction

Science, as it is, almost always wanders at a painstakingly glacial pace, and even when finished it “circles” back for self-reflection and correction, because science is never finished and never truly correct. This is the core of science, a slow, dogged and ethical pursuit of self-doubt. But then there are historical moments when science must simply just react, and when it does the ingredients are always the same: a fleeting moment of wandering brilliance, relentless perseverance, and luck. Much like the 19th century London cholera outbreak when John Snow had “his most brilliant idea:” *death rates* and *spatially mapping* 578 cholera deaths counts, the COVID-19 (2019 novel coronavirus) pandemic has been such a moment (1,2). With COVID-19 this has not been the brilliance of one or two or even three scientists, it has been the brilliance and movement of many. But when the time finally comes, as always demanded, science must circle back to evaluate and reflect. The time is now and is the current goal of this paper: to take a tiny glacial step and begin the evaluation of the COVID-19 data collection process. Our hope is that others will follow in this scientific self-critique of the COVID-19 data.

As COVID-19 slowly gained momentum in late winter and early spring of 2020, governments and other organizations scrambled to collect and present temporo-spatial data. When governments, understandably, struggled with the proliferation of COVID-19, many non-governmental organizations and universities helped with the COVID-19 data collection by innovating with data aggregation techniques (e.g., web scraping, crowd-sourcing) (1–4). Despite new technology and methods, aggregating COVID-19 data remains difficult and potentially error-ridden due to the sheer amount of data (even Snow’s much smaller cholera data underestimated deaths by 8%), the novelty of the worldwide data tracking process, and the attempt to collect community-level information

(e.g., county) (5). Due to the efforts of multiple aggregators and their various methods, the COVID-19 pandemic provides a unique opportunity to evaluate the statistical reliability of near-real time and fast-moving infectious disease surveillance data. Thus, a well-documented reliability study examining data methods and possible causes of differences between aggregators is essential knowledge for future infectious disease outbreaks.

Despite the validity challenges, as Hartley and Perencevich (6) have pointed out, leveraging continuous COVID-19 data from multiple sources to evaluate public health interventions in near real-time far outweighs the inevitable inaccuracies. In fact, technology has truly transformed the disease surveillance response to COVID-19 (7,8). Local and federal governments, hospitals, newspaper outlets, universities, the Centers for Disease Control and Prevention (CDC) and other organizations have worked together to aggregate and survey COVID-19 (9). Once collected and combined by aggregators, COVID-19 data has been used to create geo-maps and other data visualizations and statistical models to track, predict, and understand the disease (8,10,11). This aggregated COVID-19 data has helped governments and communities formulate responses, allocate resources, measure the effectiveness of policy interventions, such as stay-at-home orders, and provide guidance in loosening restrictions (12–15).

As a result, the COVID-19 data collection and reporting process has transformed, not only our ability to surveil infectious disease, but to also forecast cases and outcomes under varying scenarios (8,11,16–18). This has been integral in preventing disease and saving lives (19). While new data and technology solutions have been invaluable in easing uncertainty and providing facts in a sea of unknowns, much of the data still remains unavailable at finer resolutions than the county-level (1,7). There is also the challenge of aggregating data across government agencies that collect and

report their data differently (20–23). Information and transparency in the U.S. related to data tracking methods is often limited and varied (24) as there are numerous independently established systems for reporting disease cases and deaths (6,9). Thus, numerous challenges remain with collecting and aggregating valid and reliable COVID-19 data (24,25).

In an effort to help move “real-time” disease surveillance forward, this study attempts to make several contributions. First, we describe our COVID-19 data collection process and observations of the process, which has not previously been documented for COVID-19. Second, we examine the reliability of several COVID-19 data aggregators, including the CDC-endorsed USAFacts (USAF) (26), Johns Hopkins University (JHU) (27), New York Times (NYT) (28), The COVID Tracking Project (CTP) (29), and BroadStreet (BS),(30) at the national, state, and county levels. Lastly, it is essential to examine how COVID-19 reporting differences may be manifested in commonly used tracking statistics, thus, we examined the case fatality rate estimates at the state level.

Methods

Data collection process

Starting on March 16th, 2020, the Broadstreet team (consisting of approximately 120 volunteers) began tracking diagnosed cumulative cases of, and deaths due to COVID-19 reported by state and county governments. Following CDC guidelines published on 4/5/2020 (31), volunteers tracked case and death totals using various sources and organizing them within Google Sheets. Volunteers were organized into six regional teams consisting of members acting in daily data entry, management, and quality assurance roles. Probable cases are defined by the CDC as being:

1. Diagnosed through epidemiologically linking individuals expressing COVID-19 symptoms to a known case;
2. Tests positive for presence of antigen, and either expresses COVID-19 symptoms or is epidemiologically linked to a known case; or,
3. Meeting vital records criteria (32). All data prior to March 9th was entered from Johns Hopkins University (27) and validated through multiple methods. Between March 9th and March 16th of 2020, data was obtained retroactively from state, county, and news sources.

County-level case and death count totals were entered daily in a 24-hour cycle to track cumulative totals of the virus over time. The spreadsheet consisted of rows for each county so COVID-19 totals could be entered, as well as an “Unknown County” for cases that could not be assigned to a county. The sources used were official state or local government websites. In some cases this was supplemented with secondary sources, such as news sources, due to infrequent or nonspecific reporting by primary sources. Team managers examined the accuracy of daily totals to identify and correct errors. The Quality Assurance team then compared BroadStreet's county-level cumulative totals to those reported by other aggregators, including the NYT (28), JHU (27), CTP (29), and USAF (33), to check the validity of entered data. If significant discrepancies between aggregators existed, Quality Assurance performed research to determine the most “accurate” count totals, and then left a comment with the results of their research and any changes. All team members signed off on a tracking sheet after completing their assigned tasks to ensure accountability.

In situations where the decrease was caused by a one-day anomaly in the totals reported, this was assumed to be a reporting error and the anomalous data was updated to match the following day. In the case of a simple decrease in cumulative totals, if research did not produce an explanation of the cause, then the assumption was

made that this was due to cases or deaths being reassigned to a different county, and the historic totals in the initial county were reduced and transferred into an “Unknown County”.

In an effort to begin comparison for reliability statistical analysis, BroadStreet collected data from other COVID-19 aggregator sources, including USAF, NYT, JHU, and CTP (27,28,33). Initial examples of differences in reporting included BroadStreet reporting 89 more counties when compared to other aggregators and thousands of anomalies (number is less than previous day) in county-level case and death counts. This result is highly biased against counties with rapidly growing cases and deaths and illustrates that reported numbers are not always immediately accurate. Table 1 provides a summary of various data collection methods by the different aggregators.

Table 1. Aggregator Data Collection Methods

Variable		Aggregator				
		USAF(33)	JHU(34)	NYT(28)	CTP(29)	BS(30)
Collection Method	Web Scrapped	✓	✓			
	Manual Entry	✓	✓	✓	✓	✓
	Crowd Sourced		✓			
Source	State Health Department	✓ (Daily)		✓	✓ (Daily)	✓
	County Health Department		✓	✓	✓	✓
	Media		✓	✓		✓
Data Collected	Cases	✓ (Cumulative)	✓	✓ (Cumulative)	✓	✓
	Deaths	✓ (Cumulative)	✓	✓ (Cumulative)	✓	✓
	Testing				✓	
Quality Assurance	Revise Errors	✓	✓			✓
	Validate on other aggregators					✓

^aUSAF = USA Facts; NYT = New York Times; JHU = John Hopkins University; BS = BroadStreet; CTP = The COVID Tracking Project

Data cleaning and preparation

Each aggregator's original dataset was cleaned and pre-processed in the R statistical computing language (35) to generate comparable datasets across aggregators. This included the removal of unknown case or death data, removal of unmatched Federal Information Processing Standards (FIPS), and removal of

uncommonly reported US territories and/or smaller geographic delineations. In an effort to reduce the negative binomial skew resulting from a significant number of zero-count days (i.e., before COVID-19 was prevalent in a location), a modified date range of March 15, 2020 through June 30, 2020 was selected to reduce this concern while maximizing the inclusion of early count data.

A daily case and death count was calculated using a date's cumulative count minus the preceding date's cumulative count. Negative counts resulting from daily count calculation for cases and deaths were dropped from the dataset. Negative counts accounted for 0.77% of county case data, 0.21% of county death data, 0.05% of state case data, and 0.15% of state death data, respectively. Before conducting the reliability analyses, two other notable changes were made to the data; daily counts were smoothed using a 3-day moving average to account for asynchronous reporting of daily cases by each aggregator and all daily case and death counts were modified by +1 to remove any remaining zero-count data to improve Cohen Kappa coefficient estimates and reduce the number of paradoxical results.

The issue of smoothing is significant for several reasons. First, data were extremely unreliable prior to smoothing due to the reporting process and significant outliers in the data, thus the smoothed results presented here are more positive (i.e., possess higher reliability estimates) from a data aggregator perspective. Second, this finding suggests that government officials and media agencies should utilize and stress moving averages (or some other form of smoothed data) rather than raw new counts given their lack of reliability across data sources. This finding largely explains the significant increases and decreases in counts that are commonly seen in the data and reported by the media. These large changes in numbers are presumably not a function of large fluctuations in new cases or deaths, but instead an artifact of the data reporting

process (see *Data reporting process* below and S1 Figure). This process may create unintentional panic or claim to communities.

Data reporting process

Generally, daily COVID-19 counts are reported from a given data source (e.g., county public health websites) and then extracted by aggregators (36). The challenge with daily reporting counts is they depend on many varying factors; for example, the time and date these numbers are reported can be nearly immediate or significantly lag. This can be seen in Table 2, where the numbers of new cases often differ depending on the day and time these numbers were reported. Each aggregator reports or publishes the same day counts (e.g., cases and deaths recorded on September 12th 2020), at different times and on different days (e.g., one aggregator reports September 12, 2020 counts at the end of day on September 12, 2020, whereas another aggregator may report September 12, 2020 counts on at 8 a.m. on September 13, 2020).

For example in Table 2, both Aggregator 1 and Aggregator 3 report 67 cases on April 30, 2020, whereas Aggregator 2 reported only 19 on April 30, 2020 and the additional 48 cases the following day (May 1, 2020). While the average number of cases are comparable across data aggregators, the number of cases are rarely reliable. Because of daily inconsistencies such as this, reliability estimates were computed and compared using the raw data and a three day moving average. Given the higher reliability of the moving average, this suggests that media and government reports, along with researchers, should consider using a moving average to better represent true trends in COVID-19 cases and deaths given the increase in reliability. This is especially important in early disease tracking when case count sample sizes are small.

Table 2. Number of New COVID-19 Cases by Date and Aggregator

Date	Aggregator 1	Aggregator 2	Aggregator 3
April 23, 2020 (Thursday)	87	46	41
April 24, 2020 (Friday)	167	41	0
April 25, 2020 (Saturday)	0	28	64
April 26, 2020 (Sunday)	0	36	0
April 27, 2020 (Monday)	0	23	44
April 28, 2020 (Tuesday)	-59	21	0
April 29, 2020 (Wednesday)	32	32	32
April 30, 2020 (Thursday)	67	19	67
May 1, 2020 (Friday)	0	48	0
<i>Mean</i>	32.67	32.67	27.56

^aUSAF = USA Facts; NYT = New York Times; JHU = John Hopkins University; BS = BroadStreet; CTP = The COVID Tracking Project

Statistical analyses

To assess the inter-rater reliability (IRR) of COVID-19 aggregators based on new cases and death counts across the counties, states, and United States, a Kappa variant called linearly weighted Cohen's Kappa (LWCK) was used to examine agreement between paired aggregators due to the discrete nature of the data (37,38). LWCK inherently takes into account the influence of chance agreement, thus improving the model's sensitivity towards disagreement among rater observation pairs. Other IRR statistics were considered and examined, such as generalized linear mixed effects model intraclass correlation coefficients, intraclass correlation coefficients with mixed effects, and Spearman and Pearson correlations. Note, these statistical results often varied significantly due to large variation of data distributions and ranges, thus the LWCK statistic represents results that most closely matched the reliability quality.

After computing LWCK statistics at the county, state, and national levels, choropleth maps were generated for at each level to help visualize COVID-19 spatial event density and understand changes in reliability across aggregators and locations. While several standards have been proposed for IRR, this study employed the standard proposed by Cicchetti and Sparrow (39): Excellent (0.75 to 1.00), Good (0.60 to 0.75), Fair (0.40 to 0.60), and Poor (0 to 0.40).

Bayesian

As discussed, because it is important to examine how reliability results may manifest themselves in commonly used disease tracking statistics, we estimated case fatality rate over time (March 15, 2020 to June 15, 2020) using a novel empirical Bayes approach. Thus, for each aggregator, we used an empirical Bayes procedure to compute a posterior Beta distribution for each state's case fatality rate (March 15, 2020 to June 15, 2020), based on the number of cases and deaths reported by the corresponding aggregator.

We start with the assumption that the death counts in each state are independently sampled from beta-binomial distributions with common shape parameters α and β , and with the state-specific number of reported cases. We then estimated the global (U.S. wide) α and β parameters via maximum likelihood estimation. These shape parameters form the empirical prior for the subsequent analysis, which from this point forward is a simple Bayesian estimation of binomial proportion. With this common prior, we separately computed the posterior distribution for case fatality rate for each state, based on that state's case and death counts.

Results

U.S. level

Table 3 results provide a reliability comparison across all the aggregators at the U.S. level. These results suggest that mean (M) reliability for JHU ($M_{\text{Cases}} = 0.89$, $M_{\text{Death}} = 0.69$), NYT ($M_{\text{Cases}} = 0.89$, $M_{\text{Death}} = 0.69$), USAF ($M_{\text{Cases}} = 0.89$, $M_{\text{Death}} = 0.68$), and CTP ($M_{\text{Cases}} = 0.88$, $M_{\text{Death}} = 0.64$) displayed the highest average inter-rater agreement among the five reported aggregators for both new cases and deaths. On average, BS ($M_{\text{Cases}} = 0.75$, $M_{\text{Death}} = 0.59$) yielded consistently lower inter-rater reliability when compared to other aggregators for both the number of cases and deaths. Interestingly, lower levels of inter-rater agreement were observed across aggregators associated with the number of deaths.

Table 3. Reliability Comparisons for Each Pair of Aggregators for Cases and Deaths at U.S. Level

Aggregator at U.S. level	Cases	Deaths
USAF vs. NYT	0.956	0.778
USAF vs. JHU	0.932	0.688
USAF vs. CTP	0.917	0.712
NYT vs. CTP	0.914	0.677
JHU vs. NYT	0.930	0.736
JHU vs. CTP	0.924	0.638
BS vs. USAF	0.741	0.547
BS vs. NYT	0.745	0.583
BS vs. JHU	0.771	0.683
BS vs. CTP	0.756	0.545

^aUSAF = USA Facts; NYT = New York Times; JHU = John Hopkins University; BS = BroadStreet; CTP = The COVID Tracking Project

State level

USAF, NYT, and JHU yielded the highest inter-rater reliability across all states for both the number of cases and deaths when examining each pair (Fig 1) and for the average of these aggregator pairs (see Table 3). Average reliability for cases and deaths across all aggregators was 0.86 and 0.66, respectively. Taking a deeper look into the data, high (defined here as $\kappa \geq 0.90$) mean inter-rater reliability averaged across aggregator pairings (see Table 4) was observed across all aggregator state case comparisons for LA, VA, SD, AZ, CT, MD, NJ, and FL when examining the number of cases. Further, the average reliability for deaths was high for only SD, ME, OK, and CT. Note, several states (i.e., RI, OK, MI, NV, and KS) had unacceptable average reliability statistics (defined here as $\kappa \leq 0.70$) associated with the number of cases, and reliability was even worse for the death rates of 29 states (see Table 4).

Based on these results and other results provided in Table 4, the number of cases data were consistently more reliable than the number of deaths. Further depending on the aggregator, the variance and range in reliability within a state can be large, regardless of whether it is the number of cases or deaths. Although several examples exist, for the average number of cases and death data, CTP had a reliability of 0.76 within NY whereas BS only had a reliability of 0.23) within NY. This is important to note as it suggests that reliability is a function of both the aggregator and state.

Fig 1. Provides the intra-rater reliability between each aggregator pair as Kappas state daily counts. Darker (1.00) to lighter (0.00) color indicates more to less agreement, respectively.

State	Cases										Deaths									
	USAF vs. NYT	USAF vs. JHU	USAF vs. CTP	NYT vs. CTP	JHU vs. NYT	JHU vs. CTP	BS vs. USAF	BS vs. NYT	BS vs. JHU	BS vs. CTP	USAF vs. NYT	USAF vs. JHU	USAF vs. CTP	NYT vs. CTP	JHU vs. NYT	JHU vs. CTP	BS vs. USAF	BS vs. NYT	BS vs. JHU	BS vs. CTP
AK	0.69	0.83	0.67	0.76	0.59	0.69	0.66	0.78	0.59	0.77	0.72	0.72	0.72	0.90	0.90	1.00	0.42	0.59	0.57	0.57
AL	0.95	0.90	0.86	0.87	0.94	0.89	0.90	0.89	0.84	0.81	0.68	0.60	0.52	0.65	0.82	0.65	0.64	0.80	0.72	0.55
AR	0.88	0.84	0.58	0.69	0.81	0.64	0.93	0.88	0.83	0.58	0.89	0.85	0.51	0.59	0.92	0.57	0.85	0.91	0.85	0.56
AZ	0.95	0.98	0.97	0.93	0.95	0.96	0.94	0.94	0.93	0.92	0.69	0.72	0.85	0.73	0.70	0.78	0.72	0.64	0.66	0.74
CA	0.80	0.78	0.68	0.76	0.77	0.61	0.84	0.77	0.72	0.66	0.60	0.54	0.23	0.28	0.55	0.25	0.61	0.60	0.53	0.23
CO	0.85	0.88	0.63	0.66	0.91	0.67	0.88	0.90	0.94	0.67	0.68	0.74	0.10	0.08	0.79	0.07	0.77	0.73	0.79	0.10
CT	0.94	0.91	0.85	0.92	0.97	0.94	0.93	0.98	0.95	0.90	0.89	0.89	0.81	0.88	0.98	0.86	0.92	0.93	0.94	0.85
DC	0.87	0.84	0.83	0.95	0.95	0.95	0.63	0.66	0.63	0.62	0.84	0.84	0.80	0.96	0.97	0.94	0.48	0.43	0.46	0.42
DE	0.91	0.88	0.80	0.88	0.97	0.86	0.87	0.94	0.91	0.83	0.85	0.85	0.43	0.54	0.97	0.53	0.84	0.97	0.93	0.52
FL	0.98	0.92	0.85	0.85	0.93	0.85	0.96	0.97	0.90	0.85	0.86	0.77	0.73	0.82	0.88	0.83	0.80	0.86	0.78	0.73
GA	0.82	0.79	0.84	0.85	0.93	0.84	0.42	0.43	0.44	0.45	0.61	0.53	0.47	0.62	0.82	0.70	0.08	0.09	0.10	0.11
HI	0.84	0.79	0.52	0.48	0.83	0.46	0.80	0.84	0.71	0.47	0.86	0.85	0.45	0.42	0.87	0.47	0.87	0.94	0.90	0.41
IA	0.80	0.83	0.84	0.83	0.92	0.87	0.79	0.82	0.85	0.81	0.39	0.48	0.61	0.43	0.68	0.54	0.48	0.51	0.53	0.58
ID	0.84	0.61	0.46	0.50	0.61	0.55	0.84	0.81	0.63	0.47	0.79	0.71	0.21	0.24	0.67	0.40	0.88	0.85	0.78	0.24
IL	0.86	0.92	0.93	0.91	0.83	0.91	0.89	0.87	0.86	0.88	0.68	0.87	0.86	0.73	0.76	0.96	0.71	0.81	0.77	0.75
IN	0.85	0.86	0.87	0.90	0.89	0.99	0.51	0.56	0.50	0.51	0.60	0.60	0.59	0.89	0.94	0.93	0.17	0.13	0.12	0.12
KS	0.76	0.59	0.81	0.78	0.75	0.62	0.42	0.50	0.59	0.40	0.47	0.45	0.29	0.26	0.55	0.21	0.28	0.36	0.33	0.24
KY	0.69	0.85	0.75	0.56	0.71	0.71	0.67	0.66	0.67	0.64	0.43	0.75	0.54	0.32	0.35	0.60	0.61	0.30	0.63	0.52
LA	0.93	0.95	0.93	0.97	0.97	0.98	0.95	0.96	0.97	0.96	0.78	0.81	0.78	0.91	0.91	0.93	0.86	0.85	0.87	0.87
MA	0.93	0.35	0.89	0.95	0.39	0.40	0.89	0.95	0.39	0.95	0.89	0.86	0.68	0.78	0.97	0.76	0.85	0.95	0.92	0.73
MD	0.92	0.93	0.93	0.92	0.92	1.00	0.88	0.88	0.95	0.95	0.38	0.38	0.29	0.78	0.90	0.74	0.41	0.92	0.86	0.75
ME	0.80	0.73	0.78	0.98	0.90	0.91	0.73	0.87	0.82	0.84	0.88	0.83	0.88	1.00	0.95	0.95	0.88	0.98	0.92	0.98
MI	0.84	0.75	0.55	0.55	0.69	0.53	0.34	0.38	0.26	0.67	0.74	0.66	0.38	0.51	0.82	0.57	0.03	0.11	0.09	0.34
MN	0.93	0.90	0.57	0.59	0.97	0.61	0.93	0.99	0.97	0.59	0.80	0.78	0.80	0.99	0.97	0.96	0.79	0.88	0.85	0.88
MO	0.78	0.78	0.91	0.74	0.72	0.77	0.46	0.55	0.52	0.42	0.37	0.30	0.72	0.31	0.26	0.23	0.21	0.28	0.12	0.14
MS	0.91	0.92	0.91	0.97	0.98	0.98	0.61	0.61	0.62	0.61	0.79	0.79	0.75	0.93	0.97	0.95	0.20	0.16	0.18	0.16
MT	0.78	0.84	0.84	0.82	0.83	0.97	0.85	0.86	0.95	0.94	0.85	0.89	0.91	0.91	0.92	0.97	0.82	0.83	0.87	0.87
NC	0.79	0.62	0.89	0.84	0.65	0.61	0.87	0.83	0.63	0.92	0.41	0.39	0.81	0.50	0.42	0.51	0.77	0.52	0.45	0.85
ND	0.83	0.81	0.81	0.89	0.96	0.88	0.76	0.89	0.90	0.83	0.88	0.89	0.22	0.22	0.86	0.18	0.83	0.80	0.80	0.20
NE	0.75	0.77	0.63	0.64	0.86	0.65	0.76	0.89	0.87	0.64	0.49	0.38	0.29	0.18	0.38	0.24	0.53	0.49	0.52	0.19
NH	0.94	0.83	0.61	0.60	0.89	0.59	0.94	0.99	0.89	0.60	0.96	0.80	0.39	0.41	0.82	0.44	0.95	0.99	0.81	0.42
NJ	0.84	0.88	0.88	0.95	0.91	0.95	0.87	0.92	0.92	0.96	0.63	0.52	0.48	0.69	0.77	0.79	0.67	0.83	0.71	0.63
NM	0.91	0.77	0.47	0.50	0.83	0.58	0.89	0.97	0.81	0.51	0.83	0.83	0.33	0.34	0.84	0.39	0.89	0.94	0.86	0.36
NV	0.67	0.70	0.66	0.70	0.80	0.76	0.42	0.55	0.45	0.46	0.40	0.42	0.34	0.36	0.46	0.47	0.10	0.26	0.16	0.17
NY	0.94	0.92	0.92	0.93	0.93	0.95	0.23	0.24	0.22	0.22	0.60	0.21	0.22	0.21	0.19	0.11	0.19	0.14	0.15	-0.02
OH	0.96	0.96	0.97	1.00	0.99	1.00	0.29	0.31	0.31	0.31	0.84	0.84	0.87	0.98	0.95	0.96	0.08	0.10	0.10	0.09
OK	0.88	0.88	0.85	0.97	0.90	0.89	0.06	0.04	0.04	0.03	0.88	0.88	0.88	0.95	0.94	0.95	0.81	0.88	0.88	0.90
OR	0.95	0.93	0.95	0.92	0.90	0.91	0.50	0.51	0.49	0.49	0.72	0.81	0.77	0.66	0.68	0.88	0.09	0.09	0.11	0.10
PA	0.72	0.71	0.94	0.69	0.87	0.67	0.71	0.81	0.81	0.67	0.49	0.60	0.83	0.51	0.59	0.63	0.28	0.40	0.40	0.29
RI	0.56	0.54	0.30	0.46	0.97	0.47	0.32	0.31	0.32	0.33	0.63	0.57	0.59	0.87	0.94	0.81	0.47	0.49	0.42	0.39
SC	0.91	0.87	0.73	0.82	0.95	0.81	0.88	0.94	0.90	0.77	0.78	0.78	0.58	0.73	0.93	0.74	0.76	0.90	0.90	0.65
SD	0.92	0.94	0.93	0.99	0.98	0.97	0.93	0.96	0.97	0.97	0.89	0.90	0.89	0.97	0.98	0.98	0.90	0.97	0.98	0.97
TN	0.82	0.82	0.95	0.81	0.85	0.81	0.36	0.35	0.31	0.36	0.71	0.76	0.81	0.74	0.78	0.77	0.72	0.71	0.70	0.84
TX	0.63	0.72	0.87	0.60	0.73	0.69	0.76	0.68	0.79	0.80	0.32	0.29	0.78	0.33	0.54	0.34	0.53	0.41	0.39	0.55
UT	0.89	0.88	0.92	0.93	0.89	0.95	0.83	0.87	0.83	0.87	0.73	0.75	0.81	0.88	0.81	0.94	0.59	0.71	0.65	0.69
VA	0.94	0.94	0.95	0.96	0.94	0.96	0.96	0.97	0.96	0.98	0.70	0.71	0.78	0.90	0.90	0.91	0.67	0.80	0.82	0.83
VT	0.88	0.87	0.69	0.77	0.98	0.78	0.68	0.74	0.74	0.76	0.82	0.82	0.82	0.87	0.86	0.90	0.50	0.55	0.60	0.57
WA	0.76	0.91	0.48	0.51	0.72	0.45	0.77	0.75	0.74	0.56	0.59	0.67	0.14	0.14	0.53	0.17	0.01	0.04	-0.02	0.07
WI	0.82	0.94	0.84	0.80	0.85	0.83	0.47	0.50	0.48	0.47	0.66	0.84	0.85	0.68	0.70	0.86	-0.04	0.00	0.01	-0.02
WV	0.78	0.68	0.70	0.78	0.83	0.79	0.74	0.81	0.69	0.71	0.91	0.70	0.73	0.80	0.72	0.72	0.86	0.90	0.66	0.71
WY	0.70	0.68	0.67	0.87	0.81	0.92	0.69	0.88	0.85	0.93	0.69	0.61	0.64	0.85	0.57	0.47	0.72	0.95	0.57	0.85

County level

The maps in Figures 2 and 3 provide reliability statistics at the county level for each aggregator pair based on the number of cases and deaths, respectively. These results suggest that county-level reliability appears clustered within states, such that lower county reliability tends to reside in certain states. Perhaps more interesting is that certain pairs of aggregators are more reliable in some counties than others, thus pointing to the concern that the data collection methods used may result in significantly different conclusions (both for political and research purposes) at local levels. While it is clear from Table 4 that the level of reliability is often state dependent, Figures 2 and 3 demonstrate there is also significant variation within states.

Table 4. Average Kappa (Fig 3) for Each Aggregator by State

<u>State</u>	<u>Cases</u>						<u>Deaths</u>					
	USAF	NYT	JHU	BS	CTP	<i>M</i>	USAF	NYT	JHU	BS	CTP	<i>M</i>
AK	0.71	0.71	0.67	0.70	0.72	0.70	0.64	0.78	0.80	0.54	0.80	0.71
AL	0.90	0.91	0.89	0.86	0.86	0.88	0.61	0.74	0.70	0.68	0.59	0.66
AR	0.81	0.81	0.78	0.80	0.62	0.76	0.77	0.83	0.80	0.79	0.56	0.75
AZ	0.96	0.94	0.95	0.93	0.94	0.95	0.74	0.69	0.72	0.69	0.77	0.72
CA	0.77	0.78	0.72	0.75	0.68	0.74	0.49	0.50	0.47	0.49	0.25	0.44
CO	0.81	0.83	0.85	0.85	0.66	0.80	0.57	0.57	0.60	0.60	0.09	0.48
CT	0.91	0.95	0.94	0.94	0.90	0.93	0.88	0.92	0.92	0.91	0.85	0.90
DC	0.79	0.86	0.84	0.63	0.84	0.79	0.74	0.80	0.80	0.45	0.78	0.71
DE	0.87	0.93	0.90	0.89	0.84	0.89	0.74	0.83	0.82	0.81	0.51	0.74
FL	0.93	0.93	0.90	0.92	0.85	0.91	0.79	0.86	0.82	0.79	0.78	0.81
GA	0.72	0.76	0.75	0.43	0.75	0.68	0.42	0.53	0.54	0.09	0.47	0.41
HI	0.74	0.75	0.69	0.71	0.48	0.67	0.76	0.78	0.77	0.78	0.44	0.71
IA	0.82	0.84	0.87	0.82	0.84	0.84	0.49	0.50	0.56	0.52	0.54	0.52

ID	0.69	0.69	0.60	0.69	0.49	0.63	0.65	0.64	0.64	0.69	0.27	0.58
IL	0.90	0.87	0.88	0.88	0.91	0.89	0.78	0.75	0.84	0.76	0.83	0.79
IN	0.77	0.80	0.81	0.52	0.82	0.75	0.49	0.64	0.65	0.14	0.64	0.51
KS	0.64	0.70	0.64	0.47	0.65	0.62	0.37	0.41	0.39	0.30	0.25	0.34
KY	0.74	0.66	0.74	0.66	0.66	0.69	0.58	0.35	0.58	0.51	0.49	0.50
LA	0.94	0.96	0.97	0.96	0.96	0.96	0.81	0.86	0.88	0.86	0.87	0.86
MA	0.76	0.80	0.38	0.80	0.80	0.71	0.82	0.90	0.88	0.87	0.74	0.84
MD	0.91	0.91	0.95	0.91	0.95	0.93	0.36	0.74	0.72	0.74	0.64	0.64
ME	0.76	0.89	0.84	0.81	0.88	0.84	0.87	0.95	0.91	0.94	0.95	0.92
MI	0.62	0.62	0.56	0.41	0.58	0.56	0.45	0.55	0.53	0.14	0.45	0.42
MN	0.83	0.87	0.86	0.87	0.59	0.80	0.79	0.91	0.89	0.85	0.91	0.87
MO	0.73	0.70	0.70	0.49	0.71	0.67	0.40	0.30	0.23	0.19	0.35	0.30
MS	0.84	0.87	0.88	0.61	0.87	0.81	0.63	0.71	0.72	0.18	0.70	0.59
MT	0.83	0.82	0.90	0.90	0.89	0.87	0.87	0.88	0.91	0.85	0.91	0.88
NC	0.79	0.77	0.63	0.81	0.82	0.76	0.60	0.46	0.45	0.65	0.67	0.56
ND	0.80	0.89	0.89	0.84	0.85	0.86	0.71	0.69	0.68	0.66	0.21	0.59
NE	0.73	0.79	0.79	0.79	0.64	0.75	0.42	0.38	0.38	0.43	0.22	0.37
NH	0.83	0.86	0.80	0.85	0.60	0.79	0.77	0.79	0.71	0.79	0.41	0.70
NJ	0.87	0.90	0.91	0.91	0.93	0.91	0.58	0.73	0.70	0.71	0.65	0.67
NM	0.76	0.80	0.75	0.80	0.52	0.72	0.72	0.74	0.73	0.76	0.36	0.66
NV	0.61	0.68	0.68	0.47	0.65	0.62	0.32	0.37	0.38	0.17	0.33	0.31
NY	0.75	0.76	0.75	0.23	0.76	0.65	0.30	0.29	0.17	0.12	0.13	0.20
OH	0.80	0.82	0.82	0.31	0.82	0.71	0.66	0.72	0.71	0.09	0.72	0.58
OK	0.67	0.70	0.68	0.04	0.69	0.55	0.86	0.91	0.91	0.87	0.92	0.90
OR	0.83	0.82	0.81	0.50	0.82	0.75	0.60	0.54	0.62	0.10	0.60	0.49
PA	0.77	0.77	0.76	0.75	0.74	0.76	0.55	0.50	0.55	0.34	0.56	0.50
RI	0.43	0.58	0.57	0.32	0.39	0.46	0.57	0.73	0.68	0.44	0.66	0.62
SC	0.85	0.91	0.88	0.87	0.78	0.86	0.72	0.84	0.84	0.80	0.68	0.78
SD	0.93	0.96	0.97	0.96	0.96	0.96	0.89	0.95	0.96	0.95	0.95	0.94

TN	0.74	0.71	0.70	0.35	0.73	0.65	0.75	0.73	0.75	0.74	0.79	0.75
TX	0.74	0.66	0.73	0.76	0.74	0.73	0.48	0.40	0.39	0.47	0.50	0.45
UT	0.88	0.90	0.89	0.85	0.92	0.89	0.72	0.78	0.79	0.66	0.83	0.76
VA	0.95	0.95	0.95	0.97	0.96	0.96	0.71	0.83	0.83	0.78	0.85	0.80
VT	0.78	0.84	0.84	0.73	0.75	0.79	0.74	0.78	0.80	0.55	0.79	0.73
WA	0.73	0.68	0.70	0.70	0.50	0.66	0.35	0.33	0.34	0.02	0.13	0.23
WI	0.77	0.74	0.78	0.48	0.73	0.70	0.58	0.51	0.60	-0.01*	0.59	0.45
WV	0.72	0.80	0.75	0.74	0.74	0.75	0.80	0.83	0.70	0.78	0.74	0.77
WY	0.68	0.81	0.81	0.84	0.85	0.80	0.67	0.77	0.56	0.77	0.71	0.69
Mean	0.79	0.81	0.79	0.71	0.76	0.77	0.64	0.68	0.67	0.57	0.60	0.63

^aUSAF = USA Facts; NYT = New York Times; JHU = John Hopkins University; BS = BroadStreet; CTP = The COVID Tracking Project.

*Kappa can produce negative values 0 is random agreement among raters; 1 is complete agreement; less than 0 is generally interpreted as “no agreement.”(40)

Fig 2. Provides the reliability within each county for the number of COVID-19 cases using the reliability categories proposed by Cicchetti and Sparrow (36). Darker (1.00) to lighter (0.00) color indicates more to less agreement. For kappa, smaller sample size differences won't penalize for smaller value differences.

Fig 3. Provides the reliability within each county for the number of COVID-19 deaths using the reliability categories proposed by Cicchetti and Sparrow. Darker (1.00) to lighter (0.00) color indicates more to less agreement.

Bayesian

It is essential to examine case fatality rate (CFR) estimates and not just reliability statistics to explore how reliability estimates may translate into actual statistics used to track COVID-19. Since the empirical Bayes approach was repeated over time, we can see how the estimate for case fatality rate develops as more data becomes available (Fig 4). As time passes and more cases and deaths are reported, the intervals narrow, giving a more precise estimate for the case fatality rate. In addition, for most states, the estimates corresponding to the different aggregators begin to align with each other over time.

If we look a bit closer at the data in Figure 5 we can see how low reliability manifests itself in varying fatality estimates. For example, in NY we see reliability estimates ranging from 0.12 to 0.30 (see Table 4), which results in an aggregate fatality range of 0.063 to 0.082 (26.20% difference). If we go back and look at CFR estimate

differences across aggregators for NY we see: 0.008 to 0.016 (119.21% difference) on March 15, 2020; 0.050 to 0.076 (34.28% difference) on April 15, 2020; 0.065 to 0.083 (25.03% difference) on May 15, 2020; and 0.064 to 0.082 to (24.68% difference) on June 15, 2020. This also means our confidence in estimates will be low early on, especially when sample sizes are small. Looking at AK credible intervals (CI), its smallest lower CI is 0.007 and its largest upper CI is 0.024, which are fairly large differences for potential point estimates of fatality rates. What this implies is that low reliability across aggregators can lead to significant differences in calculated disease tracking statistics, especially early in a pandemic.

Fig 4. Time-progression of case fatality rate across states and sources. The horizontal bars represent the 90% equal-tail credible intervals, with the vertical black bars indicating the posterior means.

Fig 5. Aggregated (June 30, 2020) case fatality rate across states and sources. The horizontal bars represent the 90% equal-tail credible intervals, with the vertical black bars indicating the posterior means.

Discussion

This study attempted to compare the reliability of COVID-19 death and cases count data across national, state, and county-levels between data aggregators. As expected, given the larger sample sizes, reliability for both cases and deaths was higher at the national level across aggregators than at state and county levels. However, death count reliability was typically lower than reliability for reported cases. Variation in reliability remained across aggregators and suggests that aggregator choice could have an impact on any data analysis or subsequent action based on the data. These differences can partially be explained by the intended purposes and collections methods of each aggregator. USAF (33), JHU (27), and NYT (28) have been reporting daily cases early in the pandemic and attempt to publish case and death totals in near “real-time” or as they are reported. They occasionally use county-level health departments as a source in instances where the state health department is lagging significantly behind them. Conversely, CTP (29) exclusively uses state health departments as a source to ensure their data are consistent. Broadstreet has emphasized updating data to ensure it is following a logical trend and, when possible, updating historic data to reflect more epidemiologically significant dates, such as date of death or date of symptom onset. These disparate approaches are important for different reasons (e.g., historical accuracy for retrospective analysis) and likely caused some differences in reliability between aggregators.

State level reliability (Fig 1 and Table 4) demonstrated notable findings as well. First, reliability is not equal across states, suggesting that individual state practices and policies considerably influence the data reliability. Second, some reliability estimates are extremely poor suggesting analysis of these data could produce inconsistent findings.

These results imply the need for standardization of collection and reporting methods across states, which would increase both reliability and validity of the data.

USAF, JHU, NYT, CPT, and BS use various data collection and quality assurance methods, as well as sources (27–30,33). Using state public health departments as a data source requires less maintenance and is more sustainable, but county health departments tend to be more up-to-date than state health departments, which may be of paramount importance early in a pandemic. County health departments also report data based on Council of State and Territorial Epidemiologists (CSTE) guidelines and case definitions, which can help avoid including unreasonable cases in data (41). However, this may potentially cause datasets to include duplicate cases and cases with an unreasonable definition, making the sum of all counties overestimate the national total.

While data scraping is a quick and accurate way to enter data, it is fraught with technical challenges (e.g., updating web sites breaks the scrapping code) and in our experience is not yet feasible or quicker and more accurate than manual crowdsourcing data entry. Moreover, data scraping requires human eyes monitoring it, which may cause data to be missed in instances where the health department alters their website. Likewise, a pipeline may fail to fetch data if the health department changes how their website is formatted; especially a potential issue if volunteers are not expecting this particular county to update daily, and may not notice a fetching issue. Updating historical data to include cases and deaths by date of symptom onset or death provides significant information when analyzing spread of virus and the effectiveness of preventative measures.

In regards to case and death data the NYT attributes cases to the location they are being treated, which may provide a more accurate picture of how the virus is spreading in particular counties and states compared to using solely the date reported. Despite this, the information they use to assign cases to counties is inconsistently

provided, and the data may include out of state visitors in state totals; if these cases are also reported back to the home state, these cases will be counted twice on the national level.

Limitations

While the intent of this study was not to explain aggregator differences, a short discussion of some differences are noteworthy. For example, Broadstreet often showed significant disagreement with other aggregators in several states where they update historic case and death totals to reflect date of symptom onset, date of diagnosis, or date of death.

Consequently, as a result of challenges posed in the many stages of data analyses, the reliability and validity of these statistics is critical when creating policies to protect the public and accurately modeling the disease. Disease data validity is imperative and should be the primary objective for any institute, as without validity there can be no reliability. Given that validity cannot be assessed without significant agency and/or government oversight, this study sought to evaluate COVID-19 data reliability, providing insight into the consistency of data across different sources.

Fundamentally, the validity of any statistical analysis is based on the quality of data collected (39,41–46). Moreover, it is critical that aggregators are transparent in their data collection process so users can judge the validity of their process and can understand discrepancies in numbers across data collection sources. An important caveat is the validity of the final data source is largely dependent on the initial sources providing the data (e.g., state officials and hospitals). For this reason, it is critical that mechanisms are also put in place to evaluate the reliability and validity of data sources at this level. Unfortunately, to our knowledge there is currently no mechanism in place to evaluate this process or the accuracy of the data collected (2).

Due to validity concerns, several findings were clear when evaluating the reliability of reported daily cases and deaths across aggregators. First, a 3-day moving average is likely needed to ensure reliability across aggregators and eliminate large spikes or dips in the data associated with validity issues. To account for this, Cohen's Kappa was used, though with limitations, one being the potential for paradoxical coefficients such that high agreement yield zero-value coefficients, negative coefficients, or abnormally low coefficients (47,48). Modifying the moving average counts by +1 did improve overall kappa performance, however a handful of paradoxical results still occurred.

While it would be ideal if cases were reported using the date of infection or death rather than when the event was reported and all aggregators used these dates, this was not the case and frequently resulted in significant spikes on certain days (e.g., cases often dropped over the weekend and spiked on Monday or Tuesday, with the level of these spikes often being agency or county dependent). While the aforementioned example associated with data spikes certainly impacts the data's validity, one should be cognizant that it should not impact the reliability (i.e., aggregators should reliability report those spikes). With that said, it is clear from our evaluation of the aggregator's data that the practices applied across aggregators is not consistent (Table 3), thus practices should be put in place to increase reliability rather than relying on data smoothing methods to reduce the impact of inconsistent reporting.

Conclusions and relevance

The general conclusion from this study is that the United States needs a national public data reporting system that is free from the inconsistencies and data discrepancies that result from decentralized data collection and aggregation. The technology to make this happen currently exists. More than 95% of U.S. hospitals use an Electronic Health Record system (5), which can be integrated into a near-real-time

data reporting infrastructure to share data between local, state, and national public health agencies. Additionally, the CDC maintains a National Notifiable Diseases Surveillance System (NNDSS), which is used to aggregate data on nationally reportable and notifiable diseases. COVID-19 data are submitted electronically to the CDC by state or jurisdictional health departments via the COVID-19 Electronic Laboratory Reporting system. However, participation in reporting to the NNDSS varies widely between states because participation in the program is entirely voluntary. The problem, therefore, lies in the initial collection and eventual reporting of data from the states. Difference in the underlying Infection Fatality Rate (deaths per true number of infections, rather than deaths per detected/reported cases) would cause discrepancies if certain states had a more vulnerable populace than others, due to demographics such as age or socioeconomic status.

Another likely contributor is differences in reporting. The lack of a nation-wide standard for reporting deaths means that different states may be more or less stringent in attributing deaths to the virus. A third possible source for disagreement across states is discrimination in testing. Due to limited availability of testing, some states became more restrictive in providing free tests to the public. Tests in such states were prioritized towards those exhibiting more severe symptoms, and consequently could have introduced case sampling bias towards a higher-risk subset of the greater population of infected individuals. Through future research, different databases and public sources will be incredibly valuable in the tracking and documentation of cases and deaths (49,50).

Standardizing infectious disease data collection and dissemination would empower practitioners to do more linking to other variables and analysis. For example, the Area Deprivation Index is a powerful indicator of many health outcomes (50–52). The Centers for Disease Control and Prevention (CDC) reports social inequality and health

systems issues as a cause for an increased risk of health and socioeconomic impacts as a result of COVID-19 for these groups (53,54). Data reporting for race began in early April, with Louisiana being the first to report data (54–56). Immediately, disparities in mortality deaths were noticed, and a June 2020 report by the CDC confirmed this disparity was widespread. Ultimately, we need to nationally mandate explicit methods for reportable infectious diseases that allows for comparing data across geographic levels. This is a political problem that can only be solved with increased public health funding at all levels of government to fully modernize disease reporting in the US.

Acknowledgements

We'd like to give a special thank you to everyone who participated in the [COVID-19 Data Project](#). What a Journey it has been!

We'd also like to thank all the universities that have helped us along the way and allowed us to borrow their wonderful students for a good cause: [Simmons University](#), [New York University](#), [Temple University](#), [George Washington University](#), and many others!

Thank you to [BroadStreet](#) and [Franciscan Health](#) for continued support.

Author Contributions

Conceptualization: Tom Schmitt and Dan Sass

Data curation: COVID-19 Data Project interns

Methodology: Tom Schmitt, Dan Sass, Erik Yan and Ryan Frost.

Analysis: Dan Sass, Erik Yan, and Ryan Frost

Writing – original draft: Tom Schmitt, Dan Sass, April R. Miller, and Samin Charepoo

Writing – section contributions, reviewing & editing: April R. Miller, Samin

Charepoo, Erik Yan, Ryan W. Frost, Zachary Sturgeon, Grace Gibbon, Patrick Balius,

Cedonia Thomas, James Walters, Melanie Schmitt, Tracy Flood, Daniel Sass, and Tom

Schmitt

References

1. Whitelaw S, Mamas MA, Topol E, Van Spall HGC. Applications of digital technology in COVID-19 pandemic planning and response. *Lancet Digit Health*. 2020 Aug;2(8):e435–40.
2. Callaghan S. COVID-19 Is a Data Science Issue. *Patterns N Y N*. 2020 May 8;1(2):100022.
3. Data Collection and Reporting | NNDSS [Internet]. [cited 2021 Mar 12]. Available from: <https://wwwn.cdc.gov/nndss/data-collection.html>
4. Killeen BD, Wu JY, Shah K, Zapaishchykova A, Nikutta P, Tamhane A, et al. A County-level Dataset for Informing the United States' Response to COVID-19. *ArXiv200400756 Phys Q-Bio* [Internet]. 2020 Sep 10 [cited 2021 Mar 12]; Available from: <http://arxiv.org/abs/2004.00756>
5. Shiode N, Shiode S, Rod-Thatcher E, Rana S, Vinten-Johansen P. The mortality rates and the space-time patterns of John Snow's cholera epidemic map. *Int J Health Geogr*. 2015 Jun 17;14:21.
6. Hartley DM, Perencevich EN. Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis. *JAMA*. 2020 May 19;323(19):1908–9.
7. Budd J, Miller BS, Manning EM, Lampos V, Zhuang M, Edelstein M, et al. Digital technologies in the public-health response to COVID-19. *Nat Med*. 2020 Aug;26(8):1183–92.
8. Aiken EL, McGough SF, Majumder MS, Wachtel G, Nguyen AT, Viboud C, et al. Real-time estimation of disease activity in emerging outbreaks using internet search information. *PLOS Comput Biol*. 2020 Aug 17;16(8):e1008117.
9. Social Distancing [Internet]. [cited 2021 Mar 14]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/social-distancing.html>
10. Kamel Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbreaks and epidemics. *Int J Health Geogr*. 2020 Mar 11;19(1):8.
11. Eshragh A, Alizamir S, Howley P, Stojanovski E. Modeling the dynamics of the COVID-19 population in Australia: A probabilistic analysis. *PLOS ONE*. 2020 Oct 2;15(10):e0240153.
12. Haffajee RL, Mello MM. Thinking Globally, Acting Locally - The U.S. Response to Covid-19. *N Engl J Med*. 2020 May 28;382(22):e75.
13. CDC activities and initiatives supporting the COVID-19 response and the President's plan for opening America up again : May 2020 [Internet]. [cited 2021 Mar 12]. Available from: <https://stacks.cdc.gov/view/cdc/88478>
14. Gasser U, Ienca M, Scheibner J, Sleight J, Vayena E. Digital tools against COVID-19: taxonomy, ethical challenges, and navigation aid. *Lancet Digit Health*. 2020 Aug;2(8):e425–34.
15. Cheng C, Barceló J, Hartnett AS, Kubinec R, Messerschmidt L. COVID-19 Government Response Event Dataset (CoronaNet v.1.0). *Nat Hum Behav*. 2020 Jul;4(7):756–68.
16. Lapointe-Shaw L, Rader B, Astley CM, Hawkins JB, Bhatia D, Schatten WJ, et al. Web and phone-based COVID-19 syndromic surveillance in Canada: A cross-sectional study. *PLOS ONE*. 2020 Oct 2;15(10):e0239886.
17. Buonanno P, Galletta S, Puca M. Estimating the severity of COVID-19: Evidence from the Italian epicenter. *PLOS ONE*. 2020 Oct 1;15(10):e0239569.
18. Heerden A van, Young S. Use of social media big data as a novel HIV surveillance tool in South Africa. *PLOS ONE*. 2020 Oct 2;15(10):e0239304.
19. (COVID-19) in the U.S. Centers for Disease Control and Prevention. [Internet]. CDC. Coronavirus Disease; 2019 [cited 2020 Aug 19]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/cases-in-us.html>
20. IHME COVID-19 health service utilization forecasting team, Murray CJ. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator-days and deaths by US state

- in the next 4 months [Internet]. *Infectious Diseases (except HIV/AIDS)*; 2020 Mar [cited 2021 Mar 12]. Available from: <http://medrxiv.org/lookup/doi/10.1101/2020.03.27.20043752>
21. Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. *JAMA*. 2020 Apr 14;323(14):1341–2.
22. Brownstein NC, Louis TA, O'Hagan A, Pendergast J. The Role of Expert Judgment in Statistical Inference and Evidence-Based Decision-Making. *Am Stat*. 2019 Mar 20;73(01):56–68.
23. Adams-Huet B, Ahn C. Bridging Clinical Investigators and Statisticians: Writing the Statistical Methodology for a Research Proposal. *J Investig Med*. 2009 Dec 1;57(8):818–24.
24. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science*. 2020 May 1;368(6490):489–93.
25. Weinberger DM, Chen J, Cohen T, Crawford FW, Mostashari F, Olson D, et al. Estimation of Excess Deaths Associated With the COVID-19 Pandemic in the United States, March to May 2020. *JAMA Intern Med*. 2020 Oct 1;180(10):1336.
26. US Coronavirus Cases & Deaths by State [Internet]. USAFacts.org. 2021 [cited 2021 Mar 12]. Available from: [/visualizations/coronavirus-covid-19-spread-map](https://visualizations/coronavirus-covid-19-spread-map)
27. COVID-19 United States Cases by County [Internet]. Johns Hopkins Coronavirus Resource Center. [cited 2021 Mar 12]. Available from: <https://coronavirus.jhu.edu/us-map>
28. Coronavirus in the U.S.: Latest Map and Case Count - The New York Times [Internet]. [cited 2021 Mar 12]. Available from: <https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>
29. The COVID Tracking Project [Internet]. The COVID Tracking Project. [cited 2021 Mar 12]. Available from: <https://covidtracking.com/>
30. BroadStreet Covid19 Data Project [Internet]. [cited 2021 Mar 12]. Available from: <https://covid19datapoint.org/>
31. CDC. Coronavirus Disease 2019 Prevention (COVID-19) [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2020 Apr 5]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
32. CDC. Cases, Data, and Surveillance [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Mar 12]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html>
33. Detailed Methodology and Sources: COVID-19 Data [Internet]. USAFacts. [cited 2021 Mar 12]. Available from: <https://usafacts.org/articles/detailed-methodology-covid-19-data/>
34. Yang T, Shen K, He S, Li E, Sun P, Chen P, et al. CovidNet: To Bring Data Transparency in the Era of COVID-19. *ArXiv200510948 Cs Q-Bio* [Internet]. 2020 Jul 20 [cited 2021 Mar 14]; Available from: <http://arxiv.org/abs/2005.10948>
35. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R foundation for Statistical Computing; 2020. [Internet]. [cited 2020 Sep 10]. Available from: <https://www.r-project.org/>
36. BroadStreet-Health [Internet]. GitHub. [cited 2021 Mar 19]. Available from: <https://github.com/BroadStreet-Health>
37. Hallgren KA. Computing Inter-Rater Reliability for Observational Data: An Overview and Tutorial. *Tutor Quant Methods Psychol*. 2012;8(1):23–34.
38. Vanbelle S, Albert A. A note on the linearly weighted kappa coefficient for ordinal scales. *Stat Methodol*. 2009 Mar 1;6(2):157–63.
39. Cicchetti DV, Sparrow SA. Developing criteria for establishing interrater reliability of specific items: applications to assessment of adaptive behavior. *Am J Ment Defic*.
40. McHugh ML. Interrater reliability: the kappa statistic. *Biochem Medica*. 2012 Oct 15;22(3):276–82.
41. Thacker S. Council of State and Territorial Epidemiologists. :8.
42. Gill JR, DeJoseph ME. The Importance of Proper Death Certification During the COVID-19 Pandemic. *JAMA*. 2020 Jul 7;324(1):27.
43. WAC 246-101-220: [Internet]. [cited 2021 Mar 16]. Available from: <https://app.leg.wa.gov/wac/default.aspx?cite=246-101-220>

44. covid-19labreporting State of Washington [Internet]. State of Washington Department of Health; 2020 [cited 2021 Mar 15]. Available from: <https://www.doh.wa.gov/portals/1/documents/1600/coronavirus/20200307-covid-19labreporting.pdf>
45. Case Investigations and Contact Tracing FAQ :: Washington State Department of Health [Internet]. [cited 2021 Mar 16]. Available from: <https://www.doh.wa.gov/Emergencies/COVID19/CaseInvestigationsandContactTracing/CaselnvestigationsandContactTracingFAQ>
46. Washington Disease Reporting System General Communicable Diseases Instruction Manual [Internet]. Washington Disease Reporting System; 2018 [cited 2021 Mar 15]. Available from: <https://www.doh.wa.gov/Portals/1/Documents/Pubs/420-227-WDRS-GCDmanual.pdf>
47. High agreement but low Kappa: I. the problems of two paradoxes - Journal of Clinical Epidemiology [Internet]. [cited 2021 Mar 12]. Available from: [https://www.jclinepi.com/article/0895-4356\(90\)90158-L/pdf](https://www.jclinepi.com/article/0895-4356(90)90158-L/pdf)
48. High agreement but low kappa: II. Resolving the paradoxes - Journal of Clinical Epidemiology [Internet]. [cited 2021 Mar 12]. Available from: [https://www.jclinepi.com/article/0895-4356\(90\)90159-M/pdf](https://www.jclinepi.com/article/0895-4356(90)90159-M/pdf)
49. Publicly available COVID-19 data for analytics [Internet]. Google Cloud Blog. [cited 2021 Mar 23]. Available from: <https://cloud.google.com/blog/products/data-analytics/publicly-available-covid-19-data-for-analytics/>
50. Area Deprivation Index (ADI) – Marketplace – Google Cloud Platform [Internet]. [cited 2021 Mar 23]. Available from: <https://console.cloud.google.com/marketplace/product/broadstreet-public-data/adi?project=theta-terrain-285112>
51. Area Deprivation Index and Vulnerable Populations - How do I find them? [Internet]. [cited 2021 Mar 23]. Available from: <https://help.broadstreet.io/article/adi/>
52. BroadStreet-Health/Race-and-Ethnicity-Data [Internet]. BroadStreet-Health; 2021 [cited 2021 Mar 24]. Available from: <https://github.com/BroadStreet-Health/Race-and-Ethnicity-Data>
53. CDC. Increased Risk Factors for Exposure [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Apr 23]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/racial-ethnic-disparities/increased-risk-exposure.html>
54. CDC. Health Equity Considerations & Racial & Ethnic Minority Groups [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Apr 23]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/race-ethnicity.html>
55. CDC. Hospitalization and Death by Race/Ethnicity [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Apr 23]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html>
56. CDC. COVID Data Tracker [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Apr 23]. Available from: <https://covid.cdc.gov/covid-data-tracker>
57. Interim COVID-19 Testing Guidance for Healthcare Providers. Wash State Dep Health. 2020;4.
58. Testing for COVID-19 :: Washington State Department of Health [Internet]. [cited 2021 Mar 16]. Available from: <https://www.doh.wa.gov/Emergencies/COVID19/TestingforCOVID19>
59. What is contact tracing? [Internet]. WASHINGTON STATE DEPARTMENT OF HEALTH; 2020. Available from: <https://www.doh.wa.gov/Portals/1/Documents/1600/coronavirus/ContactTracingInfographic.pdf>
60. WAC 246-101-201: [Internet]. [cited 2021 Mar 16]. Available from: <https://app.leg.wa.gov/wac/default.aspx?cite=246-101-201>
61. CDC. Labs [Internet]. Centers for Disease Control and Prevention. 2020 [cited 2021 Mar 16]. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/lab/reporting-lab-data.html>

62. Letter to Lab Directors/Managers [Internet]. State of Washington Department of Health; 2020 [cited 2021 Mar 15]. Available from: <https://www.doh.wa.gov/portals/1/documents/1600/coronavirus/20200307-covid-19labreporting.pdf>
63. COVID-19 testing locations in King County - King County [Internet]. [cited 2021 Mar 16]. Available from: <https://www.kingcounty.gov/depts/health/covid-19/testing.aspx>
64. COVID-19 | Testing [Internet]. [cited 2021 Mar 16]. Available from: <https://www.skagitcounty.net/Departments/HealthDiseases/coronavirusdriveup.htm>
65. White House to hospitals: Bypass CDC, report COVID-19 data directly to HHS | Healthcare IT News [Internet]. [cited 2021 Apr 23]. Available from: <https://www.healthcareitnews.com/news/white-house-hospitals-bypass-cdc-report-covid-19-data-directly-hhs>

Supporting information

Washington state COVID-19 protocol

The first step in Washington state's COVID-19 protocol involves identifying the symptomatic individual (S1 Figure). This individual will either be expressing symptoms of COVID-19, is a close contact of a case of COVID-19, is at-risk of transmitting COVID-19 due to various factors (below), or is a member of a group atypically prone to adverse COVID-19 outcomes undergoes testing through a healthcare provider or at a testing site. The provider/testing site collects information during the testing process, including contact information, demographic, race and ethnicity (57).

After identification, most tests are sent to clinical labs, and in certain situations, the specimen is sent to the Public Health Lab (which tends to have shorter wait times before returning a result). This is determined by various factors, most of which are used to identify people who work/live in environments where they are more likely to transmit the virus (58,59). Next, regardless of which lab conducted testing, all results (positive, negative, and inconclusive) are shared with the local health jurisdiction (county health department). If the suspicion that an individual is carrying COVID-19 is high, a negative test will be repeated. Local health jurisdictions must be notified immediately of a positive result by telephone, regardless of the hour. Isolate or clinical specimens from a positive test must be sent to the Public Health Lab within two business days of the test result, if tested at a clinical lab (43,44,57,60).

After results are received, local health jurisdictions input case information into the Washington Disease Reporting System (WDRS) to report them to the Washington State Department of Health. The CDC is also notified through the WDRS. Data reported to the CDC is de-identified, and reported through HL7 messaging or a correctly formatted .CSV file. Case interviews/contact tracing are used to fill in any information not gathered

during the initial test. Local health jurisdictions may not be given complete contact information for individuals, delaying notification (45,46,61,62).

Individuals are then notified of positive results in various ways, depending on where they had their test done. They may receive a call from the healthcare provider, from local health jurisdictions, or from their tester. Individuals are instructed to go into isolation. Contact tracers conduct interviews to determine how the virus was contracted, where possible. Contact tracers identify close contacts, who are notified, instructed to quarantine, and monitored for two weeks for symptoms of COVID-19. Monitoring of close contacts ceases after two weeks. Isolation for COVID patients ceases after their symptoms improve, they have had at least ten days pass since initial appearance of symptoms, and have gone three days without a fever. If never symptomatic, isolation ends ten days after a positive test (45,59,63,64). This process will have slight variations depending on the laws in a given state.

The CDC allows for several methods of reporting this data (61). It is important to note that there may be numerous caveats of how COVID-19 data is reported and aggregated and ultimately making its way to the CDC. For example, on July 10, 2020 The U.S. Department of Health and Human Services (HHS) directed hospitals that perform COVID-19 testing or that use certain commercial labs to report using the HHS Protect System. Thus, some testing data bypassed the CDC and went directly to the HHS (65).

S1 Figure. Visualization of Washington state's COVID-19 protocol.

Note: Time period of this chart is July 10, 2020. Process may have been updated.